Results 181 to 190 of about 24,552 (280)

A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia. [PDF]

Blood Cancer J
Parrondo RD, Ailawadhi S, Knopf BR, Zimmerman A, Kasik CJ, Chapin D, Heslop K, Roy V, Paulus A, Chanan-Khan AA.   +9 more
europepmc   +1 more source

Discovery ofImidazo[1,2‑b]pyridazine Derivatives as Potentand Highly Selective IrreversibleBruton’s Tyrosine Kinase (BTK) Inhibitors

Dandan Zhang (228849), Jie Zhao (49409), Guiqing Xu (148569), Yue Wang (65477), Yang Li (7082), Hanxiao Ren (21367266), Jiajun Geng (21367269), Yu Du (618167), Chenchen Zhang (324804), Shouning Yang (8656365), Dongfang Liu (241581), Jiajing Gao (21096485), Yi Xiong (142047), Haoyi Zhang (2325214), Wei Li (7081), Wei Wang (17594), Di Wang (329735), Biao Li (36684), Xing He (614068), Chunhua Ma (5792261), Yuqin Jiang (6618434), Qingjie Ding (1846105)   +21 more
openalex   +1 more source

Supplementary Figure S4 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>

, 2023
Sarah E. M. Herman, Rashida Z. Mustafa, Jade Jones, Deanna H. Wong, Mohammed Farooqui, Adrian Wiestner   +5 more
openalex   +1 more source

Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA/EMA

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Expedited pathways in the United States (U.S.), European Union (EU), and Japan (JP) enable earlier access to innovative therapies for rare and serious diseases. In 2025, Japan explicitly introduced revocation provisions to its Conditional Early Approval (CEA).
Takahiro Handa, Arata Tanaka, Mayumi Shikano, Rika Wakao   +3 more
wiley   +1 more source

Targeting a Pleckstrin Homology Domain with a Lysine-Reactive Covalent Binder. [PDF]

J Med Chem
West RM, Bizga Nicolescu RC, Brear P, Wagstaff J, Blaszczyk BK, Deingruber T, Sanders MG, Pérez-Areales FJ, Spring DR, Hyvönen M.   +9 more
europepmc   +1 more source

A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation

, 2019
Francisco Lopez‐Tapia, Yan Lou, Christine Brotherton‐Pleiss, A. Kuglstatter, Sung‐Sau So, Rama K. Kondru   +5 more
openalex   +1 more source

Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

European Journal of Haematology, Volume 116, Issue 6, Page 845-849, June 2026.
ABSTRACT Introduction Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including continuous BTK inhibitor (BTKi) therapy and time‐limited regimens such as venetoclax‐obinutuzumab (Ven‐O) and ibrutinib‐venetoclax (I + V).
Rebecca Tidswell, Carolyn Owen, Mona Shafey, Sarah Perry, Nanette Cox‐Kennett, Russell Sterrett, Anthea Peters, Robert Puckrin   +7 more
wiley   +1 more source

Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA) [PDF]

, 2002
Juhana E. Heinonen, C.I.Edvard Smith, Beston F. Nore   +2 more
openalex   +1 more source

Cost‐Effectiveness of Venetoclax‐Based Treatment in Treatment‐Naïve Fit Patients With CLL Without TP53 Aberrations

European Journal of Haematology, Volume 116, Issue 6, Page 873-882, June 2026.
ABSTRACT The GAIA‐CLL13 trial showed that venetoclax‐obinutuzumab (Ven‐O) based regimens, with or without ibrutinib, offer superior efficacy compared to chemoimmunotherapy (CIT) with regards to progression free survival (PFS) in fit, treatment‐naïve (TN) CLL patients. However, their higher costs warrant a cost‐effectiveness evaluation.
Lars Holger Ehlers, Mark‐David Levin, Marjolein van der Klift, Morten Berg Jensen, Hoa Thi Tuyet Tran, Arnon P. Kater, Carsten Utoft Niemann   +6 more
wiley   +1 more source

Human resistin is critical to activation of the NLRP3 inflammasome in macrophages. [PDF]

PLoS One
Kariyawasam U, Lam W, Skinner J, Chakrabarti R, Cox A, Hassoun PM, Lin Q, Johns RA.   +7 more
europepmc   +1 more source